This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07505745 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hudson Biotech |
| Enrollment | 120 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Prediabetes; Insulin Resistance; Overweight/Obesity |
| Interventions | MOTS-c (MDP); Placebo; Route Subcutaneous injection; Regimen |
| Start | Feb 2, 2026 |
| Primary completion | Feb 14, 2027 |
| Study completion | May 17, 2028 |
| Results posted | Not yet |
| Registry last updated | Apr 1, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity.
Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index) | 12 Weeks |
| Incidence of treatment-emergent adverse events (TEAEs) | 16 weeks |
4 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
